Highlights

  • FY26 sales Revenue was $2,343.4 million, with constant-currency growth of 2%.
  • Underlying net profit was $322.4 million, while statutory net profit was $147.3 million.
  • Nucleus Nexa represented more than 95% of developed-market implant sales by June 2026.
  • Operating cash flow increased to $368.0 million and free cash flow reached $263.5 million.
  • FY27 guidance targets underlying net profit of $330 million to $350 million.

Cochlear Limited (ASX:COH) is the global leader in implantable hearing solutions, according to its official website, with products spanning cochlear and bone-conduction implant systems. The company’s FY26 result shows a year of softer implant revenue and lower margins alongside product adoption, improved cash generation and continued Investment in referral pathways. The FY27 outlook centres on gradual revenue improvement, cost discipline and targeted spending on growth initiatives.

FY26 Earnings and Cash Flow

For the year ended 30 June 2026, sales revenue was $2,343.4 million, down 1% on a reported basis but up 2% in constant currency. Underlying net profit declined 22% to $322.4 million, while statutory net profit fell to $147.3 million. Gross Margin decreased to 71% from 74%, reflecting sales mix, Manufacturing variances and foreign exchange movements.

Cash generation improved during the year. Operating Cash Flow rose to $368.0 million from $237.6 million, while free cash flow increased to $263.5 million from $122.4 million. Net cash ended FY26 at $187.7 million. The on-market share buyback remained inactive because net cash was below the company’s target level of around $200 million.

Nexa Adoption and Revenue Mix

Cochlear implant units increased 5% to 56,692, while implant revenue was flat in constant currency at $1,435.2 million. The Nucleus Nexa System accounted for more than 95% of developed-market implant sales by June 2026 and achieved an average 3% price increase. Services revenue rose 6% in constant currency to $634.9 million, while Acoustics revenue increased 1% in constant currency to $273.3 million.

Research and development spending increased 15% to $323.2 million as the company continued work on product programs including the drug-eluting electrode and totally implantable cochlear implant. Cochlear is also expanding initiatives intended to improve adult referral pathways and make hearing-loss diagnosis and treatment more systematic.

Dividend and FY27 Guidance

The final ordinary Dividend was $1.30 per share, 85% franked, taking the FY26 total to $3.45 per share. The full-year payout represented 70% of underlying net profit.

For FY27, Cochlear expects low single-digit constant-currency sales revenue growth and underlying net profit of $330 million to $350 million. Gross margin is expected to be approximately 70% to 71%. Guidance also assumes Capital Expenditure of $100 million to $110 million, R&D investment of around 13% of sales revenue and completion of the Cloud Computing program during FY27.

Key Insights

Cochlear’s FY26 performance reflects the interaction of product transition, revenue mix, manufacturing efficiency and currency movements. The Nexa rollout and higher cash flow provide operational reference points for FY27, while the company’s guidance indicates only a gradual recovery in earnings. Progress in adult referral pathways, developed-market implant demand, gross margin and execution of the product pipeline remain central measures of performance.